文献速递呼吸道感染

非HIV成人肺孢子菌肺炎早期使用糖皮质激素与结局无关

Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome.
PubMed 文献 · Chest · 2018-04-26

该回顾性队列研究纳入2006至2016年Mayo Clinic收治的323例非HIV肺孢子菌肺炎住院患者,比较早期(48小时内)使用激素者与未使用者第5天SOFA呼吸评分改善情况。结果显示早期激素与第5天SOFAresp改善更少相关,30天死亡率22.9%,两组在死亡率、住院时长、ICU入住及机械通气需求上无差异。

要点

  • 非HIV肺孢子菌肺炎早期加用激素未改善呼吸结局。
  • 两组30天死亡率、住院时长、ICU入住及机械通气需求无差异。

核心结论

  • 在非HIV肺孢子菌肺炎成人中,早期加用糖皮质激素与抗肺孢子菌治疗未带来呼吸结局改善。

研究设计与样本

  • 回顾性队列研究,纳入2006至2016年Mayo Clinic收治的非HIV肺孢子菌肺炎阳性住院患者323例。
  • 早期激素组258例(48小时内使用),未用激素组65例。
  • 采用多变量逻辑回归和倾向性匹配分析比较第5天SOFA呼吸评分(SOFAresp)较基线的变化。

主要发现

  • 总体30天死亡率为22.9%(95%CI 18.2-27.4)。
  • 两组在死亡率、住院时长、ICU入住及机械通气需求方面均无差异。

临床怎么用

  • 对于非HIV肺孢子菌肺炎成人,不应仅以改善呼吸结局为目的常规早期加用糖皮质激素。

局限性

  • 回顾性队列设计,早期激素组与未用激素组样本量差异较大(258例对65例)。
  • 单中心研究,人群以白人为主(92%),外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence supporting adjunctive corticosteroids during the treatment of Pneumocystis jirovecii pneumonia (PcP) in adults without HIV is minimal and controversial. METHODS: This retrospective cohort study included P jirovecii pneumonia-positive, hospitalized patients without HIV admitted to the Mayo Clinic from 2006 to 2016. Change from baseline in the respiratory component of the Sequential Organ Failure Assessment score (SOFAresp) at day 5 was compared between early (within 48 h) steroid recipients and nonrecipients by using multivariable logistic regression and in a propensity-matched analysis. RESULTS: Among the 323 included patients (early steroids, n = 258; no steroids, n = 65), the median (interquartile range) age was 65 (53, 73) years, 63% were male, and 92% were white. Severity-adjusted regression and propensity-matched analyses found that early administration of steroids was associated with less improvement in SOFAresp at day 5 compared with no steroids (P = .001 and P = .017, respectively). No differences were observed in the odds of having at least a one-point improvement in SOFAresp at day 5 compared with baseline between groups (adjusted OR, 0.76 [95% CI, 0.24-2.28]; P = .61). Overall 30-day mortality was 22.9% (95% CI, 18.2-27.4). No differences in mortality, length of stay, admission to the ICU, or need for mechanical ventilation were found between early steroid recipients and nonrecipients. CONCLUSIONS: The addition of early corticosteroids to anti-Pneumocystis therapy in patients without HIV was not associated with improved respiratory outcomes.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Wieruszewski PM, Barreto JN, Frazee E, et al. Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome. Chest. 2018. PMID: 29705221. doi:10.1016/j.chest.2018.04.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。